Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF- and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
Figure 2
Influence of TNF-α blocking therapy on the serum TNF-α concentration in patients with ankylosing spondylitis and rheumatoid arthritis. Serum samples were taken at the indicated time points of therapy with infliximab (a) and etanercept (b). Significant changes in the TNF-α concentration during the course of therapy are indicated by the values. To test for interference of TNF-α blockers, standard curves were performed using TNF-α ELISA in the presence of either 3 μg/mL etanercept or 5 μg/mL infliximab (c).
